Monash researcher awarded $700K grant to help support leading research

In a positive step forward for industries such as agriculture, pharmaceutical science and veterinary medicine, a project aiming to regulate the way active agents are released from degradable polymeric scaffolds has received over $700k in funding as part of the Australian Research Council (ARC) Linkage Program/Projects grants.

The Monash Institute of Pharmaceutical Sciences (MIPS) project is one of five Monash University initiatives to receive a share of $2.5 million in Linkage Program grants announced by Federal Education Minister Dan Tehan.


The project, led by Dr John Quinn, is in collaboration with long-standing MIPS industry partner, PolyActiva, which seeks to apply a unique drug-polymer conjugate technology to enable site-specific delivery from materials such as implants, gels, films, or fibres. Professor Tom Davis, who retains a research position at MIPS, is also part of the investigatory team.

The Linkage Program promotes research partnerships between researchers and business, industry, community organisations and other publicly funded research agencies. By supporting the development of partnerships, the ARC encourages the transfer of skills, knowledge and ideas as a basis for securing commercial and other research benefits.

Director of MIPS, Professor Chris Porter, said the additional Government funding for this project underlined the Faculty’s strength in both drug delivery research and industry partnerships.

"PolyActiva is a long-standing, highly regarded partner of MIPS and this grant really is a testament to the value of that partnership,” says Professor Porter.

“On behalf of MIPS, I’d like to congratulate Dr Quinn and Professor Davis, and Drs Tait, Donohue and Valade and the fantastic team at PolyActiva for their success in the latest ARC Linkage funding announcement. We look forward to watching this outstanding research program continue to flourish.”

The MIPS funded project:

Next generation polymeric scaffolds for dual agent deliveryDr John Quinn and his team will provide a novel suite of degradable polymeric scaffolds for releasing multiple active agents, with tailored release profiles by utilising both polymer and small molecule synthesis techniques. The expected outcome is the establishment of design criteria for tailoring the release of active agents from the polymer scaffold. This should provide significant benefits by developing a new technology platform that could be readily adapted to applications in agriculture, pharmaceutical science and veterinary medicine where controlled release is required.

For a full list of recipients, please visit:

Contact: Kate Carthew

Phone: 9903 9619